Skip to main content

Table 2 Resource use and costs by frequency of episode (12 weeks)

From: Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis

Resources for every 12 weeks

Unit cost

No migraine

(0 MMD)

Low-frequency episode

(1–3 MMD)

Intermediate-frequency episode

(4–7 MMD)

High-frequency episode

(8–14 MMD)

Chronic migraine

(15 + MMD)

Unit

% pat

Unit

% pat

Unit

% pat

Unit

% pat

Unit

% pat

Hospitalisation

€2,044.61

-

-

1

5%

1

7%

1

7%

1

17%

Emergency visits

€227.70

-

-

1

29%

1

54%

1

74%

1

72%

Appointment with primary care doctor

€74.87

-

-

1

97%

-

-

-

-

-

-

Appointment with specialist (neurologist)

€104.36

-

-

1

4%

1

50%

1

100%

1

100%

Pharmacy visit (5 min)a

€5.89

-

-

-

-

1

100%

1

100%

1

100%

Triptans

€0.00

€0.80–€3.80

€5.30–€9.70

€11.20–€20.20

€21.70–€41.10

Other medication

€3.56

€6.20–€8.20

€6.20–€8.20

€8.90–€12.90

€13.50–€22.20

  1. MMD Monthly migraine days
  2. aOnly applicable to hospital-dispensed drugs